Nyxoah S.A. (NYXH)
USD 6.12
(1.75%)
USD 6.12
(1.75%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 124.15 Million EUR | -15.0% |
| 2022 | 146.07 Million EUR | -14.49% |
| 2021 | 170.83 Million EUR | 49.75% |
| 2020 | 114.08 Million EUR | 650.77% |
| 2019 | 15.19 Million EUR | -15.48% |
| 2018 | 17.97 Million EUR | 61.32% |
| 2017 | 11.14 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 113.01 Million EUR | -8.97% |
| 2024 Q2 | 148.23 Million EUR | 31.16% |
| 2023 Q1 | 150.95 Million EUR | 3.34% |
| 2023 Q3 | 134.6 Million EUR | -5.48% |
| 2023 Q4 | 124.15 Million EUR | -7.76% |
| 2023 Q2 | 142.41 Million EUR | -5.66% |
| 2023 FY | 124.15 Million EUR | -15.0% |
| 2022 Q1 | 165.97 Million EUR | -2.84% |
| 2022 FY | 146.07 Million EUR | -14.49% |
| 2022 Q4 | 146.07 Million EUR | -10.97% |
| 2022 Q3 | 164.07 Million EUR | -1.69% |
| 2022 Q2 | 166.88 Million EUR | 0.55% |
| 2021 Q4 | 170.83 Million EUR | 0.0% |
| 2021 FY | 170.83 Million EUR | 49.75% |
| 2021 Q2 | 108.4 Million EUR | -2.03% |
| 2021 Q1 | 110.65 Million EUR | -3.01% |
| 2020 Q1 | - EUR | -100.0% |
| 2020 Q4 | 114.08 Million EUR | 0.0% |
| 2020 Q3 | 114.08 Million EUR | 198.9% |
| 2020 Q2 | 38.16 Million EUR | 0.0% |
| 2020 FY | 114.08 Million EUR | 650.77% |
| 2019 Q1 | - EUR | 0.0% |
| 2019 Q4 | 15.19 Million EUR | 0.0% |
| 2019 Q3 | 15.19 Million EUR | 0.0% |
| 2019 FY | 15.19 Million EUR | -15.48% |
| 2018 FY | 17.97 Million EUR | 61.32% |
| 2017 FY | 11.14 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 180.36 Million USD | 31.165% |
| AngioDynamics, Inc. | 317.67 Million USD | 60.916% |
| AtriCure, Inc. | 613.93 Million USD | 79.777% |
| Avinger, Inc. | 13.77 Million USD | -801.649% |
| Azenta, Inc. | 2.88 Billion USD | 95.698% |
| BioLife Solutions, Inc. | 412.71 Million USD | 69.917% |
| The Cooper Companies, Inc. | 11.65 Billion USD | 98.935% |
| Daxor Corporation | 34.86 Million USD | -256.066% |
| Ekso Bionics Holdings, Inc. | 28.91 Million USD | -329.342% |
| Femasys Inc. | 27.75 Million USD | -347.319% |
| GlucoTrack, Inc. | 4.9 Million USD | -2431.233% |
| Harvard Bioscience, Inc. | 137.36 Million USD | 9.616% |
| Hologic, Inc. | 9.15 Billion USD | 98.644% |
| ICU Medical, Inc. | 4.37 Billion USD | 97.164% |
| Intuitive Surgical, Inc. | 15.44 Billion USD | 99.196% |
| KORU Medical Systems, Inc. | 28.46 Million USD | -336.236% |
| LeMaitre Vascular, Inc. | 346.77 Million USD | 64.197% |
| Innovative Eyewear, Inc. | 6.21 Million USD | -1896.491% |
| Innovative Eyewear, Inc. | 6.21 Million USD | -1896.491% |
| Masimo Corporation | 3.04 Billion USD | 95.918% |
| Microbot Medical Inc. | 8.32 Million USD | -1391.017% |
| Meihua International Medical Technologies Co., Ltd. | 171.91 Million USD | 27.78% |
| Merit Medical Systems, Inc. | 2.32 Billion USD | 94.66% |
| Nephros, Inc. | 11.86 Million USD | -946.767% |
| NovoCure Limited | 1.14 Billion USD | 89.167% |
| NEXGEL, Inc. | 9.95 Million USD | -1147.182% |
| NEXGEL, Inc. | 9.95 Million USD | -1147.182% |
| Singular Genomics Systems, Inc. | 265.46 Million USD | 53.231% |
| OraSure Technologies, Inc. | 482.84 Million USD | 74.286% |
| Pro-Dex, Inc. | 54.21 Million USD | -129.03% |
| Pulse Biosciences, Inc. | 60.8 Million USD | -104.192% |
| Predictive Oncology Inc. | 14.41 Million USD | -761.17% |
| Precision Optics Corporation, Inc. | 16.91 Million USD | -634.111% |
| QuidelOrtho Corporation | 8.56 Billion USD | 98.55% |
| Repligen Corporation | 2.82 Billion USD | 95.604% |
| Sanara MedTech Inc. | 73.87 Million USD | -68.072% |
| STAAR Surgical Company | 488.69 Million USD | 74.594% |
| Sharps Technology, Inc. | 11.78 Million USD | -953.136% |
| Utah Medical Products, Inc. | 135.45 Million USD | 8.343% |
| DENTSPLY SIRONA Inc. | 7.37 Billion USD | 98.315% |
| Jin Medical International Ltd. | 32.9 Million USD | -277.337% |